Novel Telemedicine-Delivered Prolonged Exposure Therapy for Treating PTSD in Individuals With OUD
Eligible age
18+ yrs
Accepts
All genders
Locations
1 state
Healthy volunteers
No
See if you qualify for this study
Answer a few quick questions about your location and health. Takes about a minute.
About this study
Among individuals with opioid use disorder (OUD), posttraumatic stress disorder (PTSD) presents a significant clinical challenge. The prevalence of PTSD is substantially higher in individuals with OUD than in the general population, with nearly 90% reporting lifetime trauma exposure and 33% meeting diagnostic criteria for PTSD. The primary objective of this study is to evaluate the efficacy of a novel telemedicine-delivered prolonged exposure therapy protocol for improving PE attendance and reducing PTSD symptom severity in individuals with concurrent PTSD and OUD.
Sponsor: University of Vermont
You may qualify if…
- ✓ \>18 years old
- ✓ Maintained on a stable methadone or buprenorphine dose for \>1 month prior to the study
- ✓ Meet current DSM-5 posttraumatic stress disorder criteria based on the Clinician Administered PTSD Scale for DSM-5
- ✓ Participants receiving psychotropic medications must be maintained on a stable dose for \>1 month prior to enrollment.
You may not qualify if…
- ✕ Current delusions or hallucinations, unstable bipolar disorder, imminent risk for suicide as assessed by the Mini International Neuropsychiatric Interview
- ✕ Cognitive impairment as evidenced by scores \<22 on the Videoconference-based Mini Mental Status Examination (MMSE; Folstein, et al., 1975)
- ✕ Enrolled in another ongoing evidence-based treatment for PTSD.
- ✕ Pregnancy as verified by pregnancy test
- ✕ No access to cellular service
Where it's recruiting
Burlington
Source: ClinicalTrials.gov · NCT06288711 · last updated 2026-05-18